Arthneeti

Ambalal Sarabhai Enterprises Share Price & Earnings Call Analysis

₹34.83-1.42% today
Market cap
₹267 Cr
P/E
18.74
ROE
12.38%
PEG
1.12
Price to sales
1.29
Debt to equity
0.36
52W high / low
₹48.3 / ₹23.8
Sales growth (5Y)
4.35%
EBITDA margin
7.15%
Net profit margin
9.13%
Promoter holding
31.36%
Sales (last year)
₹206 Cr

Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Ambalal Sarabhai rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Ambalal Sarabhai.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Ambalal Sarabhai

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Ambalal Sarabhai

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +44.4436.1040.0143.1154.3540.7044.7045.9764.8140.3444.4552.0065.49
Expenses +41.0940.0739.0040.5849.7040.2342.1646.6759.5138.8844.0947.9259.79
Operating Profit3.35-3.971.012.534.650.472.54-0.705.301.460.364.085.70
OPM %7.54%-11.00%2.52%5.87%8.56%1.15%5.68%-1.52%8.18%3.62%0.81%7.85%8.70%
Other Income +5.711.372.851.634.792.302.805.76-5.378.361.621.943.02
Interest0.990.950.920.990.900.951.221.140.961.010.960.701.42
Depreciation0.921.051.141.130.250.981.010.991.020.881.060.961.05
Profit before tax7.15-4.601.802.048.290.843.112.93-2.057.93-0.044.366.25
Tax %20.14%5.87%40.00%34.31%-8.69%59.52%15.76%23.89%-86.83%-3.66%1,300.00%16.51%-4.00%
Net Profit +5.71-4.871.081.339.020.352.622.23-0.278.22-0.563.646.50
EPS in Rs0.75-0.640.140.171.180.050.340.29-0.041.07-0.070.470.85

Financials of Ambalal Sarabhai

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +124132134125150133163197170173196202
Expenses +129145137137144136165171162167187190
Operating Profit-4-13-3-126-3-22586912
OPM %-3%-10%-2%-9%4%-2%-1%13%5%3%5%6%
Other Income +1395-22582440331210515
Interest1045334323654
Depreciation5174223223444
Profit before tax-662-1488153354157519
Tax %13%22%34%84%48%6%10%13%25%15%-2%4%
Net Profit +-748-1814142947116518
EPS in Rs-0.876.28-2.380.170.551.833.836.161.490.740.642.32
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Ambalal Sarabhai

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital777777777777777777777777
Reserves-86-38-51-50-46-32-34354606382
Borrowings +464742434031282745465157
Other Liabilities +13294931281441111088470677966
Total Liabilities169180160197214186210231246250270281
Fixed Assets +917272595857575885888791
CWIP193142401124002
Investments1855918273332293232
Other Assets +769280119123110125128125133151156
Total Assets169180160197214186210231246250270281

Financials of Ambalal Sarabhai

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-8-755-719-7-21169-1813
Cash from Investing Activity +1080-318-917105-17-513-10
Cash from Financing Activity +-1-3-6-2-6-14-6-199-3-2-2
Net Cash Flow12-483-42-3-21-61
Free Cash Flow112189-10716-156-207
CFO/OP90%551%-252%-107%453%134%22%60%120%217%-160%114%

Financials of Ambalal Sarabhai

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days7483791008479875259558286
Inventory Days867266756176584862587568
Days Payable139135138207191184184151131133158125
Cash Conversion Cycle22206-32-46-29-39-50-10-19-229
Working Capital Days-318-156-185-187-190-140-88-25-43-35-2513
ROCE %-19%-44%-1%-5%16%25%18%34%11%7%9%12%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals